Holding the Orexin Line: Harmony’s Defining Quarter
Record WAKIX revenue and a first clinical readout for BP-205 put Harmony’s two-pronged story in focus, even as the orexin race heats up.
HRMY · Earnings Call · 2026-08-04
A defining quarter
Harmony Biosciences reported second-quarter net revenue of $261.3 million, up 30% year-over-year, and reiterated full-year guidance of $1.0-1.04 billion. The company is now on track to cross the $1 billion mark for the first time, a milestone that once seemed aspirational when WAKIX launched in 2019. The stock has followed suit, rising 32% over the last 90 days and closing near a 52-week high. As CEO Jeffrey Dayno put it, “This was a defining quarter for Harmony Biosciences on 2 fronts.” — Jeffrey Dayno, Chief Executive Officer · 2026-08-04 One is commercial, the other is pipeline: the first clinical readout for BP-205, its orexin-2 receptor agonist, which is central to the company’s long-term growth narrative. The commercial engine remains remarkably steady. WAKIX added 450 average patients sequentially, the second-highest quarterly increase in the brand’s history, and the company continues to differentiate its only non-scheduled treatment in a market where polypharmacy is the norm. Commercial execution, field force expansion, and payer coverage are all contributing to a trajectory that supports the guidance range.BP-205: Finally a Clinical Signal
The headline catalyst was the single ascending dose (SAD) Phase I data for BP-205, which Harmony positions as a potential best-in-class orexin 2 receptor agonist. The molecule showed a mean half-life of approximately 25 hours, supporting once-daily dosing, a short Tmax (30-75 minutes) for rapid onset, and dose-proportional exposure with no age or gender differences. Equally important, the safety profile was clean—no cardiovascular, hepatic, or visual signals, and only mild adverse events. “We observed a mean half-life of approximately 25 hours across dose group, which supports once-daily dosing and the potential for durable efficacy throughout the day and into the early evening,” — Kumar Budur, Chief Medical Officer · 2026-08-04 said Chief Medical Officer Kumar Budur. This is a meaningful step-up from prior quarters. In May, management had only committed to disclosing “single ascending dose clinical PK data in the middle of this year.” — Kumar Budur, Chief Medical Officer · 2026-05-07 Now that data is out, and the company is already pointing to a dense near-term catalyst path: MAD data in Q4, a sleep-deprived healthy volunteer study starting in Q3, and multiple Phase II trials in CNS indications beginning mid-2027. The company is also leaning into the multiple data catalysts storyline to build conviction around BP-205’s best-in-class potential.Competitive Positioning
The orexin-2 agonist field is crowded, with Takeda and Alkermes ahead in development. Harmony has consistently argued that potency and selectivity matter more than being first. In its view, BP-205’s high potency and over-600-fold selectivity for OX2R over OX1R provides a unique window to treat not only narcolepsy but also broader CNS disorders. As Peter Anastasiou put it,That confidence was echoed by the prior quarter’s tone, when the company signaled it would not rush into patients without first bracketing the dose range—its deliberate approach is now paying off with data that appears competitive on PK and tolerability.First isn't necessarily best, and we believe that we are developing what's emerging to be the best profile.